231 related articles for article (PubMed ID: 32146550)
1. Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer.
Broekman KE; Hof MAJ; Touw DJ; Gietema JA; Nijman HW; Lefrandt JD; Reyners AKL; Jalving M
Invest New Drugs; 2020 Oct; 38(5):1454-1462. PubMed ID: 32146550
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
3. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
[TBL] [Abstract][Full Text] [Related]
4. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Moore KN; Birrer MJ; Marsters J; Wang Y; Choi Y; Royer-Joo S; Lemahieu V; Armstrong K; Cordova J; Samineni D; Schuth E; Vaze A; Maslyar D; Humke EW; Hamilton EP; Liu JF
Gynecol Oncol; 2020 Sep; 158(3):631-639. PubMed ID: 32534811
[TBL] [Abstract][Full Text] [Related]
5. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
7. A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.
Vergote I; Oaknin A; Baurain JF; Ananda S; Wong S; Su X; Wu B; Zhong Z; Warner D; Casado A
Eur J Cancer; 2014 Sep; 50(14):2408-16. PubMed ID: 25037684
[TBL] [Abstract][Full Text] [Related]
8. An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).
Lee SW; Kim YM; Kim YT; Kang SB
J Gynecol Oncol; 2017 May; 28(3):e26. PubMed ID: 28028994
[TBL] [Abstract][Full Text] [Related]
9. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Vergote I; Amant F; Oskay-Oezcelik G; Musib L; Michel AL; Darstein C; Kania M; Bauknecht T; Sehouli J
Int J Gynecol Cancer; 2009 Dec; 19(9):1505-10. PubMed ID: 19955926
[TBL] [Abstract][Full Text] [Related]
11. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
Siddiqui N; Boddy AV; Thomas HD; Bailey NP; Robson L; Lind MJ; Calvert AH
Br J Cancer; 1997; 75(2):287-94. PubMed ID: 9010040
[TBL] [Abstract][Full Text] [Related]
12. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Jandial DA; Brady WE; Howell SB; Lankes HA; Schilder RJ; Beumer JH; Christner SM; Strychor S; Powell MA; Hagemann AR; Moore KN; Walker JL; DiSilvestro PA; Duska LR; Fracasso PM; Dizon DS
Gynecol Oncol; 2017 May; 145(2):236-242. PubMed ID: 28341300
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
Morgan MA; Darcy KM; Rose PG; DeGeest K; Bookman MA; Aikins JK; Sill MW; Mannel RS; Allievi C; Egorin MJ;
Gynecol Oncol; 2008 Sep; 110(3):329-35. PubMed ID: 18597837
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.
du Bois A; Lück HJ; Bauknecht T; Möbus V; Bochtler H; Diergarten K; Meerpohl HG
Ann Oncol; 1997 Apr; 8(4):355-61. PubMed ID: 9209665
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; de Bono JS; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; De Grève J; Schellens JHM
Invest New Drugs; 2020 Aug; 38(4):1096-1107. PubMed ID: 31637669
[TBL] [Abstract][Full Text] [Related]
18. A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer.
Gibbs DD; Pyle L; Allen M; Vaughan M; Webb A; Johnston SR; Gore ME
Br J Cancer; 2002 May; 86(9):1379-84. PubMed ID: 11986767
[TBL] [Abstract][Full Text] [Related]
19. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
20. A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma.
Micha JP; Rettenmaier MA; Bohart RD; Goldstein BH
J Gynecol Oncol; 2023 Mar; 34(2):e15. PubMed ID: 36509462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
